Considerations in the Management of Moderate to Severe Psoriatic Arthritis

Elaine Husni, MD, is joined by her Cleveland Clinic colleagues Leonard Calabrese, DO, and Anthony Fernandez, MD, for a discussion on considerations in the management of psoriatic arthritis from both rheumatologic and dermatologic perspectives.

Video 1: Emerging Treatment MOAs – IL-23 and JAK Inhibitors

Drs. Husni, Calabrese, and Fernandez discuss the mechanisms of action in IL-23 inhibitors and JAK inhibitors, and considerations for prescribing these treatment options during the COVID-19 pandemic.

Up Next

Video 1: Emerging Treatment MOAs – IL-23 and JAK Inhibitors
Video 2: Co-Management to Optimize Patient Outcomes
Video 3: Evidence-Based Wellness Strategies

About the Panel

Dr. Bardia Photo

Elaine Husni, MD, MPH

  • Vice Chair,
  • Department of Rheumatic and Immunologic Diseases, Cleveland Clinic,
  • Cleveland, Ohio
Dr. Hurvitz Photo

Leonard H. Calabrese, DO

  • Professor, Department of Medicine,
  • Cleveland Clinic Lerner College of Medicine, Case Western Reserve University,
  • University of California, Los Angeles
  • Cleveland, Ohio
Dr. Brufsky Photo

Anthony P. Fernandez, MD, PhD,

  • Assistant Clinical Professor, Department of Medicine,
  • Cleveland Clinic Lerner College of Medicine, Case Western Reserve University,
  • Cleveland, Ohio
Disclosures

Dr Husni has disclosed being a consultant for: AbbVie; Amgen; BMS; Janssen; Pfizer; Eli Lilly and Company; Novartis; UCB; Regeneron.

Dr Calabrese has disclosed that he was a consultant for: Amgen; AbbVie; Bristol-Myers Squibb; Genentech; Janssen; UCB; Horizon; Sanofi-Genzyme; Regeneron; Crescendo; GlaxoSmithKline; Pfizer; Eli Lilly and Company; Gilead; and a guest speaker for: AbbVie; Bristol-Myers Squibb; Genentech; Janssen; Horizon; Eli Lilly and Company; Celgene; Sanofi; Regeneron; Novartis

Dr Fernandez has served as director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Novartis; Mallinckrodt. He also discloses that he has been a speaker for: AbbVie; Novartis; Mallinckrodt.